Revital Healthcare receives $3.9 million grant
from Bill & Melinda Gates Foundation
Revital Healthcare (EPZ) Limited, has made an exciting announcement today. The prestigious Bill & Melinda Gates Foundation has granted the company a generous funding of close to $4 million. This substantial financial support aims to facilitate the expansion of Revital’s production capacity for auto-disable vaccine syringes. With this boost, Revital aims to significantly ramp up their syringe production from around 72 million units per year to nearly 265 million units by the end of 2022. Such a substantial increase in output will effectively address over half of Africa’s routine immunization requirements.
The global demand for auto-disable syringes has witnessed an unprecedented surge throughout 2021. This heightened demand can be attributed to the widespread distribution of COVID-19 vaccines worldwide. However, concerning projections have emerged indicating a potential shortage of auto-disable syringes in 2022. Should this shortage come to pass, it would have severe consequences for crucial vaccination initiatives, including the ongoing COVID-19 immunization efforts and the introduction of new malaria vaccines. The impact would be particularly acute in low- and middle-income countries, with Africa bearing a significant burden.
Expanding manufacturing capacity in Africa for critical supplies like syringes is essential to ensure adequate supply for the continent. We are proud to be part of global efforts to help ensure that Africans have access to life-saving vaccination. Revital Healthcare’s goal is to become the largest medical disposable manufacturer in Africa by 2030, helping the continent produce more of its own crucial healthcare commodities.
Sales, Marketing & Development Director at Revital Healthcare
Revital’s expansion of manufacturing capacity will not only enhance the global supply chain for syringes but also contribute to geographical diversification, mitigating transportation costs and ensuring a stable syringe supply in Africa. While there are more than 20 auto-disable syringe manufacturers worldwide who have been prequalified by the World Health Organization (WHO), Revital Healthcare (EPZ) Limited stands out as the sole WHO prequalified manufacturer in Africa, entrusted with the supply of vaccine syringes by UNICEF and WHO.
The urgency to address the imminent shortage of syringes required for safe COVID-19 vaccination has become increasingly paramount with the availability of new vaccines. We take pride in supporting a significant expansion of syringe manufacturing in Africa, specifically tailored to meet the continent’s needs and ensure a consistent supply of reliable auto-disable syringes for COVID-19 vaccination and the prevention of various other diseases.
Through the grant provided, Revital Healthcare will increase its production output to 265 million syringes annually by the end of 2022, pending regulatory approval. While this expansion is a notable step forward, it alone may not be sufficient to stabilize the market and address other bottlenecks within the supply chain. Therefore, it becomes imperative to contemplate the establishment of a resilient global supply chain structure capable of adapting to change. The location of manufacturers, as evident in the case of syringes, holds significant importance.
This endeavor has also served as a valuable lesson for products that historically exhibited stable demand. Prior to the pandemic, supplier mapping and accurate insight into production capacity were lacking. Collaborating with partners, we are learning to dynamically forecast amidst the volatility of the present and the uncertainty of the future. This experience has underscored the vital role of coordinated planning within both the vaccine and syringe manufacturing industries. All these efforts are crucial in preserving the life-saving impact of every vaccine delivered to people across the globe.
With the increasing availability of new vaccines against COVID-19, we are on the verge of critical shortages of the syringes needed to safely vaccinate people. We’re proud to be supporting a significant expansion of syringe manufacturing in Africa, for Africa, to assure a stable supply of safe auto-disable syringes for vaccinating people against COVID-19 and a host of other preventable diseases.
Director of Global Delivery Programs at the Bill & Melinda Gates Foundation
In the midst of the worldwide distribution of COVID-19 vaccines, there has been a remarkable increase in the global demand for auto-disable syringes. Noting the surge, Revital Healthcare has secured substantial funding to meet the escalating needs.
This funding not only enables Revital to expand its production capacity but also paves the way for the creation of numerous employment opportunities. Revital anticipates that this support will result in the establishment of more than 100 direct jobs and over 5,000 indirect jobs. Moreover, in a commendable commitment to gender equality, Revital has pledged to ensure that at least 50% of the new hires are women.
Revital’s aspirations extend beyond the immediate expansion of syringe manufacturing. The company envisions a continuous expansion strategy that encompasses the production of diverse medical devices. By doing so, Revital aims to generate further employment opportunities, stimulate economic growth, and contribute to the advancement of low- and middle-income countries (LMICs). While it is noteworthy that there are over 20 auto-disable syringe manufacturers globally who have been prequalified by the World Health Organization (WHO), Revital Healthcare (EPZ) Limited stands as the exclusive WHO prequalified manufacturer for vaccine syringes in Africa. This distinction has led to contracts with UNICEF and WHO for syringe supply, highlighting Revital’s pivotal role in addressing healthcare needs on the continent.
With the support from organizations such as the Bill & Melinda Gates Foundation, Revital is one step closer in ensuring that we fight these deadly diseases that are killing millions of people worldwide, especially in low- and middle-income countries
Chairman, Revital Healthcare.
More From This Category
Press ReleaseRevital Healthcare EPZ Ltd. Achieves WHO Prequalification for Early-Activation Auto-Disable Syringe: A Milestone for African Manufacturing and Immunization ProgrammingRevital Healthcare EPZ Ltd. stands as the exclusive African manufacturer granted WHO PQ...
Blog News &UpdatesRevital Healthcare banks blanket contractfrom a key global organisationRevital Healthcare has recently secured a notable contract with a global organization to supply India with 50 million units of 2ML vaccine syringes amidst concerns over a...
Blog News &UpdatesRevital becomes sole company in African to manufacture Covid-19 vaccine syringesRevital Healthcare (EPZ) Limited has gained international recognition for its efforts in the fight against the Covid-19 pandemic. The company has earned the...
Blog News &UpdatesUkraine using Revital-made bCPAP device to save premature babiesPremature babies in Ukraine with breathing difficulties are being saved by a device made in Kenya. The bCPAP device, produced by Africa's largest medical manufacturer - Revital...
Blog News &UpdatesRevital Exported 70 Million Covid-19 Vaccine SyringesRevital Healthcare has been globally acknowledged for its role in exporting more than 70 million Covid-19 vaccine syringes during the pandemic. The then President of Kenya, Uhuru Kenyatta,...
Blog News &UpdatesRevital unveils bCPAP - first-ever non-electric respiratory device to save babiesRevital Healthcare has achieved a remarkable feat by becoming the world's first manufacturer of a respiratory device specifically designed to support neonates and...